Xenetic Biosciences, Inc. (XBIO)

NASDAQ: XBIO · IEX Real-Time Price · USD
0.420
-0.029 (-6.46%)
Mar 30, 2023, 1:21 PM EDT - Market open
-6.46%
Market Cap 6.37M
Revenue (ttm) 1.71M
Net Income (ttm) -6.55M
Shares Out 15.17M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,090
Open 0.445
Previous Close 0.449
Day's Range 0.393 - 0.445
52-Week Range 0.240 - 1.250
Beta 2.78
Analysts Buy
Price Target 4.08 (+871.43%)
Earnings Date May 11, 2023

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug del... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Jeffrey F. Eisenberg Esq.
Employees 4
Stock Exchange NASDAQ
Ticker Symbol XBIO
Full Company Profile

Financial Performance

In 2022, XBIO's revenue was $1.71 million, an increase of 47.06% compared to the previous year's $1.16 million. Losses were -$6.55 million, 16.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 871.43% from the latest price.

Price Target
$4.08
(871.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Ph...

1 week ago - Accesswire

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET - FRENCH...

2 weeks ago - Accesswire

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 ...

2 weeks ago - Accesswire

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techn...

2 months ago - Accesswire

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...

3 months ago - Accesswire

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the ...

4 months ago - Accesswire

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of...

5 months ago - Accesswire

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer ...

Other symbols: VNRX
6 months ago - Accesswire

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techno...

6 months ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...

7 months ago - Accesswire

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic Advancing lead DNase program towards Phase 1 study for...

8 months ago - Accesswire

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing ...

Other symbols: VNRX
8 months ago - Accesswire

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications Systemic DNase program initially targeting multi-billion-dollar i...

9 months ago - Accesswire

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET - FRENCHTOWN, ...

10 months ago - Accesswire

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET FRAMINGHAM, MA /...

10 months ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical co...

11 months ago - Accesswire

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potentia...

11 months ago - Accesswire

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the potenti...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

- XCARTTM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA ...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private...

1 year ago - Accesswire

Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for

Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc. (NASDAQ:...

1 year ago - Accesswire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T pl...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies  Strong royalty growth with PolyXen® platform technology  Bolstered cash position with recently c...

1 year ago - Accesswire

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platfo...

1 year ago - Accesswire